山東誠匯雙達藥業有限公司誠摯邀請您蒞臨?2025日本東京制藥原料展覽會(CPHI Japan)?，
與我們在?6A-07展位?共話合作機遇，探討行業前沿趨勢!
展會速覽
?
時間?：2025年4月9日-11日?
地點?：日本東京有明國際會展中心?
規模?：全球50余國逾800家展商參展，預計吸引超3萬名專業觀眾?
聚焦領域?：原料藥、生物試劑、天然提取物、制藥技術及法規動態?
作為亞洲制藥行業標桿展會，CPHI Japan匯聚全球頂尖企業，
是鏈接技術革新、市場洞察與供應鏈合作的核心平臺?。
日本憑借領先的研發實力與嚴苛質量標準，持續引領制藥行業創新方向?。
關于我們
我們將攜?局麻類、抗病毒類、心腦血管類、抗腫瘤類、獸藥原料?等核心產品亮相，展現高純度原料藥與中間體的研發實力?。
（部分產品展示如下，如需了解更多產品請聯系我們）
| 產品名稱 | CAS |
| *Vonoprazan Fumarate | 1260141-27-2 |
| 881681-01-2 | |
| *Letermovir | 917389-32-3 |
| *Dapagliflozin propanediol monohydrate | 960404-48-2 |
| *Crisaborole | 906673-24-3 |
| Sugammadex sodium | 343306-79-6 |
| *Apalutamide | 956104-40-8 |
| *Baloxavir Marboxil | 1985606-14-1 |
| *Lotilaner | 1369852-71-0 |
| *Ruxolitinib Phosphate | 941678-49-5 |
| *Finerenone | 1050477-31-0 |
| *Upadacitinib | 1310726-60-3 |
| *Ozenoxacin | 245765-41-7 |
| *Resmetirom | 920509-32-6 |
| *Fexuprazan HCI | 1902954-87-3 |
| Prilocaine | 721-50-6 |
| Lidocaine HCI | 6108-05-0 |
| Lidocaine | 137-58-6 |
| Ozagrel sodium | 189224-26-8 |
| Celecoxib | 169590-42-5 |
| Ropivacaine HCI | 132112-35-7 |
| Tetracaine HCI | 136-47-0 |
| Tetracaine | 94-24-6 |
| Prilocaine HCI | 1786-81-8 |
| Pramoxine HCI | 637-58-1 |
| Bupivacaine HCI | 73360-54-0 |
| Bupivacaine | 2180-92-9 |
| Articaine HCI | 23964-57-0 |
| Tadalafil | 171596-29-5 |
| Lacidipine | 103890-78-4 |
| Urapidil HCI | 64887-14-5 |
| *Bilastin | 202189-78-4 |
| *Fluralaner | 864731-61-3 |
| *Afoxolaner | 1093861-60-9 |
| *Sarolaner | 1398609-39-6 |
| *Oclacitinib maleate | 1208319-27-0 |
|
獸藥中間體 Veterinary intermediates |
|
| 4-acetyl-2-methylbenzoic acid | 55860-35-0 |
| 2-AMino-N-(2,2,2-trifluoroethyl)acetaMide hydrochloride | 1171331-39-7 |
| 3',5'-dichloro-2,2,2-trifluoroacetophenone | 130336-16-2 |
| 4-acetyl-1-naphthoic acid | 131986-05-5 |
| 1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone | 1125812-58-9 |
| 4-(5-(3-chloro-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-1-naphthoic acid | 1308362-48-2 |
| Trans-4-aminocyclohexanecarboxylic acid hydrochloride | 27960-59-4 |
| N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide maleate | 1640292-55-2 |
|
瑪巴洛沙韋中間體 Baloxavir Marboxil Intermediates |
|
| (R)-7-(benzyloxy)- 3,4,12,12a-tetrahydro- 1H-[1,4]oxazino[3,4- c]pyrido[2,1-f][1,2,4]- triazine-6,8-dione | 1985607-70-2 |
| 3-(Benzyloxy)-4-oxo-4h-pyran-2-carboxylic acid | 119736-16-2 |
| 7,8-difluoro-6,11-dihydro-Dibenzo[b,e]thiepin-11-ol | 1985607-83-7 |
|
富馬酸伏諾拉生中間體 Vonoprazan Fumarate Intermediates |
|
| 5-(2-fluorophenyl)-1H-Pyrrole-3-carboxaldehyde | 881674-56-2 |
| Pyridine-3-sulfonyl chloride | 16133-25-8 |
|
依度沙班中間體 Edoxaban Intermediates |
|
| (1S,4S,5S)-4-Bromo-6-oxabicyclo[3.2.1]octan-7-one | 139893-81-5 |
| tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate | 1210348-34-7 |
| tert-butyl (1R,2S,5S)-2-aMino-5-(diMethylcarbaMoyl)cyclohexylcarbaMate | 365998-36-3 |
| 2-bromo-5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine;4-methylbenzenesulfonic acid | 852291-42-0 |
*All our products are not offered in countries where valid patents exist. All responsibility with repect to third parties patent rights in specific countries lies exclusively with the buyers.
*The advanced intermediates of all above APIs are available
期待與您同行?
此次參展，我們期待與全球伙伴深化合作，共同應對行業挑戰，探索新興市場機遇。
歡迎您蒞臨?6A-07展位?，通過CPHI Japan這一全球舞臺，誠匯雙達愿與您攜手，共筑制藥原料行業新未來!?
聯系我們
電話?：+86-531-58897029/7070
郵箱：market@chsdpharma.com
網站：www.chsdpharma.com
2025年4月，東京有明，不見不散!?
END
